http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 24 Aug 2026 19:30:22 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Astellas+begins+Phase+3+trial+of+ASP2138+for+gastric+cancer/26969496.html <p>Astellas Pharma Inc. (TSE: 4503) announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138, an investigational bispecific antibody, in combination with chemotherapy and pembrolizumab as a first-line treatment for adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive and HER2-negative.</p> <p>ASP2138 is administered subcutaneously and is designed to bind to CLDN18.2, a protein expressed on certain tumor cells, and CD3-positive T cells. The mechanism is intended to bring T cells closer to CLDN18.2-expressing tumor cells to activate an anti-tumor response.</p> <p>The Phase 3 study is a randomized, double-blind, http://www.streetinsider.com/FDA/Astellas+begins+Phase+3+trial+of+ASP2138+for+gastric+cancer/26969496.html Mon, 24 Aug 2026 19:30:22 -0400 4503 ALPMY O.05105702 http://www.streetinsider.com/FDA/Astellas+begins+Phase+3+trial+of+ASP2138+for+gastric+cancer/26969496.html <p>Astellas Pharma Inc. (TSE: 4503) announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138, an investigational bispecific antibody, in combination with chemotherapy and pembrolizumab as a first-line treatment for adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive and HER2-negative.</p> <p>ASP2138 is administered subcutaneously and is designed to bind to CLDN18.2, a protein expressed on certain tumor cells, and CD3-positive T cells. The mechanism is intended to bring T cells closer to CLDN18.2-expressing tumor cells to activate an anti-tumor response.</p> <p>The Phase 3 study is a randomized, double-blind, http://www.streetinsider.com/FDA/Astellas+begins+Phase+3+trial+of+ASP2138+for+gastric+cancer/26969496.html Mon, 24 Aug 2026 19:30:22 -0400 4503 ALPMY O.05105702 http://www.streetinsider.com/FDA/Astellas+begins+Phase+3+trial+of+ASP2138+for+gastric+cancer/26969496.html <p>Astellas Pharma Inc. (TSE: 4503) announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138, an investigational bispecific antibody, in combination with chemotherapy and pembrolizumab as a first-line treatment for adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive and HER2-negative.</p> <p>ASP2138 is administered subcutaneously and is designed to bind to CLDN18.2, a protein expressed on certain tumor cells, and CD3-positive T cells. The mechanism is intended to bring T cells closer to CLDN18.2-expressing tumor cells to activate an anti-tumor response.</p> <p>The Phase 3 study is a randomized, double-blind, http://www.streetinsider.com/FDA/Astellas+begins+Phase+3+trial+of+ASP2138+for+gastric+cancer/26969496.html Mon, 24 Aug 2026 19:30:22 -0400 4503 ALPMY O.05105702 http://www.streetinsider.com/Press+Releases/Astellas+Doses+First+Patient+in+Phase+3+Study+of+ASP2138+in+CLDN18.2-postive+and+HER2-negative+locally+advanced+unresectable+or+metastatic+gastric+or+gastroesophageal+junction+%28GEJ%29+adenocarcinoma/26969495.html <div class="xn-content"> <p class="prntac">-<i> ASP2138's advancement into Phase <money>3 marks</money> an important milestone in Astellas' commitment to advancing research in CLDN18.2 with its differentiated portfolio, spanning approved treatments and investigational assets -</i> </p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4503" idsrc="xmltag.org" >Astellas Pharma Inc.</span> (TSE: 4503, President and CEO: <person>Naoki Okamura</person>, "Astellas") today announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chemotherapy and pembrolizumab as first-line treatment in adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors are Claudin 18.2 (CLDN18.2)-positive http://www.streetinsider.com/Press+Releases/Astellas+Doses+First+Patient+in+Phase+3+Study+of+ASP2138+in+CLDN18.2-postive+and+HER2-negative+locally+advanced+unresectable+or+metastatic+gastric+or+gastroesophageal+junction+%28GEJ%29+adenocarcinoma/26969495.html Mon, 24 Aug 2026 19:30:00 -0400 4503 4503 ALPMY O.05105702 http://www.streetinsider.com/Press+Releases/Astellas+Doses+First+Patient+in+Phase+3+Study+of+ASP2138+in+CLDN18.2-postive+and+HER2-negative+locally+advanced+unresectable+or+metastatic+gastric+or+gastroesophageal+junction+%28GEJ%29+adenocarcinoma/26969495.html <div class="xn-content"> <p class="prntac">-<i> ASP2138's advancement into Phase <money>3 marks</money> an important milestone in Astellas' commitment to advancing research in CLDN18.2 with its differentiated portfolio, spanning approved treatments and investigational assets -</i> </p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4503" idsrc="xmltag.org" >Astellas Pharma Inc.</span> (TSE: 4503, President and CEO: <person>Naoki Okamura</person>, "Astellas") today announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chemotherapy and pembrolizumab as first-line treatment in adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors are Claudin 18.2 (CLDN18.2)-positive http://www.streetinsider.com/Press+Releases/Astellas+Doses+First+Patient+in+Phase+3+Study+of+ASP2138+in+CLDN18.2-postive+and+HER2-negative+locally+advanced+unresectable+or+metastatic+gastric+or+gastroesophageal+junction+%28GEJ%29+adenocarcinoma/26969495.html Mon, 24 Aug 2026 19:30:00 -0400 4503 4503 ALPMY O.05105702 http://www.streetinsider.com/Press+Releases/Astellas+Doses+First+Patient+in+Phase+3+Study+of+ASP2138+in+CLDN18.2-postive+and+HER2-negative+locally+advanced+unresectable+or+metastatic+gastric+or+gastroesophageal+junction+%28GEJ%29+adenocarcinoma/26969495.html <div class="xn-content"> <p class="prntac">-<i> ASP2138's advancement into Phase <money>3 marks</money> an important milestone in Astellas' commitment to advancing research in CLDN18.2 with its differentiated portfolio, spanning approved treatments and investigational assets -</i> </p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4503" idsrc="xmltag.org" >Astellas Pharma Inc.</span> (TSE: 4503, President and CEO: <person>Naoki Okamura</person>, "Astellas") today announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chemotherapy and pembrolizumab as first-line treatment in adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors are Claudin 18.2 (CLDN18.2)-positive http://www.streetinsider.com/Press+Releases/Astellas+Doses+First+Patient+in+Phase+3+Study+of+ASP2138+in+CLDN18.2-postive+and+HER2-negative+locally+advanced+unresectable+or+metastatic+gastric+or+gastroesophageal+junction+%28GEJ%29+adenocarcinoma/26969495.html Mon, 24 Aug 2026 19:30:00 -0400 4503 4503 ALPMY O.05105702 http://www.streetinsider.com/Press+Releases/Astellas+Doses+First+Patient+in+Phase+3+Study+of+ASP2138+in+CLDN18.2-postive+and+HER2-negative+locally+advanced+unresectable+or+metastatic+gastric+or+gastroesophageal+junction+%28GEJ%29+adenocarcinoma/26969495.html <div class="xn-content"> <p class="prntac">-<i> ASP2138's advancement into Phase <money>3 marks</money> an important milestone in Astellas' commitment to advancing research in CLDN18.2 with its differentiated portfolio, spanning approved treatments and investigational assets -</i> </p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4503" idsrc="xmltag.org" >Astellas Pharma Inc.</span> (TSE: 4503, President and CEO: <person>Naoki Okamura</person>, "Astellas") today announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chemotherapy and pembrolizumab as first-line treatment in adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors are Claudin 18.2 (CLDN18.2)-positive http://www.streetinsider.com/Press+Releases/Astellas+Doses+First+Patient+in+Phase+3+Study+of+ASP2138+in+CLDN18.2-postive+and+HER2-negative+locally+advanced+unresectable+or+metastatic+gastric+or+gastroesophageal+junction+%28GEJ%29+adenocarcinoma/26969495.html Mon, 24 Aug 2026 19:30:00 -0400 4503 4503 ALPMY O.05105702 http://www.streetinsider.com/PRNewswire/Astellas+Doses+First+Patient+in+Phase+3+Study+of+ASP2138+in+CLDN18.2-postive+and+HER2-negative+locally+advanced+unresectable+or+metastatic+gastric+or+gastroesophageal+junction+%28GEJ%29+adenocarcinoma/26969495.html <div class="xn-content"> <p class="prntac">-<i> ASP2138's advancement into Phase <money>3 marks</money> an important milestone in Astellas' commitment to advancing research in CLDN18.2 with its differentiated portfolio, spanning approved treatments and investigational assets -</i> </p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4503" idsrc="xmltag.org" >Astellas Pharma Inc.</span> (TSE: 4503, President and CEO: <person>Naoki Okamura</person>, "Astellas") today announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chemotherapy and pembrolizumab as first-line treatment in adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors are Claudin 18.2 (CLDN18.2)-positive http://www.streetinsider.com/PRNewswire/Astellas+Doses+First+Patient+in+Phase+3+Study+of+ASP2138+in+CLDN18.2-postive+and+HER2-negative+locally+advanced+unresectable+or+metastatic+gastric+or+gastroesophageal+junction+%28GEJ%29+adenocarcinoma/26969495.html Mon, 24 Aug 2026 19:30:00 -0400 4503 4503 ALPMY O.05105702 http://www.streetinsider.com/PRNewswire/Astellas+Doses+First+Patient+in+Phase+3+Study+of+ASP2138+in+CLDN18.2-postive+and+HER2-negative+locally+advanced+unresectable+or+metastatic+gastric+or+gastroesophageal+junction+%28GEJ%29+adenocarcinoma/26969495.html <div class="xn-content"> <p class="prntac">-<i> ASP2138's advancement into Phase <money>3 marks</money> an important milestone in Astellas' commitment to advancing research in CLDN18.2 with its differentiated portfolio, spanning approved treatments and investigational assets -</i> </p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4503" idsrc="xmltag.org" >Astellas Pharma Inc.</span> (TSE: 4503, President and CEO: <person>Naoki Okamura</person>, "Astellas") today announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chemotherapy and pembrolizumab as first-line treatment in adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors are Claudin 18.2 (CLDN18.2)-positive http://www.streetinsider.com/PRNewswire/Astellas+Doses+First+Patient+in+Phase+3+Study+of+ASP2138+in+CLDN18.2-postive+and+HER2-negative+locally+advanced+unresectable+or+metastatic+gastric+or+gastroesophageal+junction+%28GEJ%29+adenocarcinoma/26969495.html Mon, 24 Aug 2026 19:30:00 -0400 4503 4503 ALPMY O.05105702 http://www.streetinsider.com/PRNewswire/Astellas+Doses+First+Patient+in+Phase+3+Study+of+ASP2138+in+CLDN18.2-postive+and+HER2-negative+locally+advanced+unresectable+or+metastatic+gastric+or+gastroesophageal+junction+%28GEJ%29+adenocarcinoma/26969495.html <div class="xn-content"> <p class="prntac">-<i> ASP2138's advancement into Phase <money>3 marks</money> an important milestone in Astellas' commitment to advancing research in CLDN18.2 with its differentiated portfolio, spanning approved treatments and investigational assets -</i> </p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4503" idsrc="xmltag.org" >Astellas Pharma Inc.</span> (TSE: 4503, President and CEO: <person>Naoki Okamura</person>, "Astellas") today announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chemotherapy and pembrolizumab as first-line treatment in adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors are Claudin 18.2 (CLDN18.2)-positive http://www.streetinsider.com/PRNewswire/Astellas+Doses+First+Patient+in+Phase+3+Study+of+ASP2138+in+CLDN18.2-postive+and+HER2-negative+locally+advanced+unresectable+or+metastatic+gastric+or+gastroesophageal+junction+%28GEJ%29+adenocarcinoma/26969495.html Mon, 24 Aug 2026 19:30:00 -0400 4503 4503 ALPMY O.05105702 http://www.streetinsider.com/PRNewswire/Astellas+Doses+First+Patient+in+Phase+3+Study+of+ASP2138+in+CLDN18.2-postive+and+HER2-negative+locally+advanced+unresectable+or+metastatic+gastric+or+gastroesophageal+junction+%28GEJ%29+adenocarcinoma/26969495.html <div class="xn-content"> <p class="prntac">-<i> ASP2138's advancement into Phase <money>3 marks</money> an important milestone in Astellas' commitment to advancing research in CLDN18.2 with its differentiated portfolio, spanning approved treatments and investigational assets -</i> </p><p><span class="legendSpanClass"><location value="LU/jp..tokyo" idsrc="xmltag.org" >TOKYO</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="Tokyo:4503" idsrc="xmltag.org" >Astellas Pharma Inc.</span> (TSE: 4503, President and CEO: <person>Naoki Okamura</person>, "Astellas") today announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chemotherapy and pembrolizumab as first-line treatment in adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors are Claudin 18.2 (CLDN18.2)-positive http://www.streetinsider.com/PRNewswire/Astellas+Doses+First+Patient+in+Phase+3+Study+of+ASP2138+in+CLDN18.2-postive+and+HER2-negative+locally+advanced+unresectable+or+metastatic+gastric+or+gastroesophageal+junction+%28GEJ%29+adenocarcinoma/26969495.html Mon, 24 Aug 2026 19:30:00 -0400 4503 4503 ALPMY O.05105702 http://www.streetinsider.com/Intl+Ratings/CLSA+Starts+Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+at+Outperform+%282%29/26941023.html <p>CLSA analyst Matthew Yan initiates coverage on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) with a Outperform (2) rating and a price target of JPY3,000.00.</p> http://www.streetinsider.com/Intl+Ratings/CLSA+Starts+Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+at+Outperform+%282%29/26941023.html Tue, 18 Aug 2026 08:25:42 -0400 ALPMY http://www.streetinsider.com/Intl+Ratings/CLSA+Starts+Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+at+Outperform+%282%29/26941023.html <p>CLSA analyst Matthew Yan initiates coverage on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) with a Outperform (2) rating and a price target of JPY3,000.00.</p> http://www.streetinsider.com/Intl+Ratings/CLSA+Starts+Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+at+Outperform+%282%29/26941023.html Tue, 18 Aug 2026 08:25:42 -0400 ALPMY http://www.streetinsider.com/New+Coverage/CLSA+Starts+Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+at+Outperform+%282%29/26941023.html <p>CLSA analyst Matthew Yan initiates coverage on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) with a Outperform (2) rating and a price target of JPY3,000.00.</p> http://www.streetinsider.com/New+Coverage/CLSA+Starts+Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+at+Outperform+%282%29/26941023.html Tue, 18 Aug 2026 08:25:42 -0400 ALPMY http://www.streetinsider.com/New+Coverage/CLSA+Starts+Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+at+Outperform+%282%29/26941023.html <p>CLSA analyst Matthew Yan initiates coverage on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) with a Outperform (2) rating and a price target of JPY3,000.00.</p> http://www.streetinsider.com/New+Coverage/CLSA+Starts+Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+at+Outperform+%282%29/26941023.html Tue, 18 Aug 2026 08:25:42 -0400 ALPMY http://www.streetinsider.com/Intl+Ratings/Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+PT+Raised+to+JPY2%2C500+at+JPMorgan/26933747.html JPMorgan analyst Seiji Wakao raised the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,500.00 (from JPY2,300.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+PT+Raised+to+JPY2%2C500+at+JPMorgan/26933747.html Mon, 17 Aug 2026 02:31:33 -0400 ALPMY http://www.streetinsider.com/Intl+Ratings/Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+PT+Raised+to+JPY2%2C500+at+JPMorgan/26933747.html JPMorgan analyst Seiji Wakao raised the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,500.00 (from JPY2,300.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+PT+Raised+to+JPY2%2C500+at+JPMorgan/26933747.html Mon, 17 Aug 2026 02:31:33 -0400 ALPMY http://www.streetinsider.com/Analyst+PT+Change/Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+PT+Raised+to+JPY2%2C500+at+JPMorgan/26933747.html JPMorgan analyst Seiji Wakao raised the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,500.00 (from JPY2,300.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+PT+Raised+to+JPY2%2C500+at+JPMorgan/26933747.html Mon, 17 Aug 2026 02:31:33 -0400 ALPMY http://www.streetinsider.com/Analyst+PT+Change/Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+PT+Raised+to+JPY2%2C500+at+JPMorgan/26933747.html JPMorgan analyst Seiji Wakao raised the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,500.00 (from JPY2,300.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+PT+Raised+to+JPY2%2C500+at+JPMorgan/26933747.html Mon, 17 Aug 2026 02:31:33 -0400 ALPMY http://www.streetinsider.com/Intl+Ratings/Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+PT+Lowered+to+JPY2%2C300+at+JPMorgan/26702532.html JPMorgan analyst Seiji Wakao lowered the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,300.00 (from JPY2,500.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+PT+Lowered+to+JPY2%2C300+at+JPMorgan/26702532.html Mon, 29 Jun 2026 08:29:31 -0400 ALPMY http://www.streetinsider.com/Intl+Ratings/Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+PT+Lowered+to+JPY2%2C300+at+JPMorgan/26702532.html JPMorgan analyst Seiji Wakao lowered the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,300.00 (from JPY2,500.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+PT+Lowered+to+JPY2%2C300+at+JPMorgan/26702532.html Mon, 29 Jun 2026 08:29:31 -0400 ALPMY http://www.streetinsider.com/Analyst+PT+Change/Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+PT+Lowered+to+JPY2%2C300+at+JPMorgan/26702532.html JPMorgan analyst Seiji Wakao lowered the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,300.00 (from JPY2,500.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+PT+Lowered+to+JPY2%2C300+at+JPMorgan/26702532.html Mon, 29 Jun 2026 08:29:31 -0400 ALPMY http://www.streetinsider.com/Analyst+PT+Change/Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+PT+Lowered+to+JPY2%2C300+at+JPMorgan/26702532.html JPMorgan analyst Seiji Wakao lowered the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,300.00 (from JPY2,500.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29+PT+Lowered+to+JPY2%2C300+at+JPMorgan/26702532.html Mon, 29 Jun 2026 08:29:31 -0400 ALPMY http://www.streetinsider.com/Intl+Ratings/Goldman+Sachs+Reiterates+Buy+Rating+on+Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29/26649350.html <p>Goldman Sachs analyst Akinori Ueda reiterated a Buy rating and JPY2,950.00 price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY).</p> http://www.streetinsider.com/Intl+Ratings/Goldman+Sachs+Reiterates+Buy+Rating+on+Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29/26649350.html Tue, 16 Jun 2026 00:22:06 -0400 ALPMY http://www.streetinsider.com/Intl+Ratings/Goldman+Sachs+Reiterates+Buy+Rating+on+Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29/26649350.html <p>Goldman Sachs analyst Akinori Ueda reiterated a Buy rating and JPY2,950.00 price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY).</p> http://www.streetinsider.com/Intl+Ratings/Goldman+Sachs+Reiterates+Buy+Rating+on+Astellas+Pharma+Inc+%284503%3AJP%29+%28ALPMY%29/26649350.html Tue, 16 Jun 2026 00:22:06 -0400 ALPMY